Faricimab for Wet AMD: What You Should Know
How Faricimab Works
Faricimab takes a different approach from earlier wet AMD medications by blocking two proteins that contribute to abnormal blood vessel growth and fluid leakage in the retina. Understanding these two pathways helps explain why this dual-targeting approach may offer benefits over single-pathway treatments.
Vascular endothelial growth factor A, or VEGF-A, is a protein that signals the body to grow new blood vessels. In wet AMD, abnormally high levels of VEGF-A in the retina trigger the growth of fragile, leaky blood vessels that originate beneath the retina, a process called choroidal neovascularization. These abnormal vessels leak fluid and blood into the surrounding retinal tissue, causing swelling, distortion, and damage to the light-sensing cells responsible for central vision. Blocking VEGF-A has been the foundation of wet AMD treatment for nearly two decades, and earlier medications targeting this protein have helped millions of patients protect their vision.
Angiopoietin-2, or Ang-2, is a second protein that plays an important role in the vascular changes seen in wet AMD. Ang-2 disrupts a signaling system that normally keeps blood vessel walls stable and intact, making vessels more permeable and more sensitive to the damaging effects of VEGF-A. Elevated Ang-2 levels also promote inflammation and attract inflammatory cells to the retina. In patients with wet AMD, both VEGF-A and Ang-2 are elevated, and their combined activity drives a more aggressive disease process than either pathway would produce on its own.
Faricimab is engineered as a bispecific antibody, which means it has two functional arms that each bind to a different target. One arm blocks VEGF-A, preventing abnormal vessel growth and leakage. The other arm blocks Ang-2, reducing vascular instability and its proinflammatory effects. By neutralizing both proteins at once, faricimab aims to stabilize the retinal blood vessels more comprehensively than a VEGF-only approach. This broader mechanism of action is designed to reduce fluid accumulation in the retina more effectively and potentially for a longer duration between treatments.
What the Clinical Evidence Shows
Faricimab received FDA approval based on two large, well-designed clinical trials that compared it directly to an established wet AMD treatment. The results provide meaningful guidance about what patients can realistically expect.
The FDA approval of faricimab for wet AMD was supported by two phase three clinical trials, TENAYA and LUCERNE, which together enrolled more than 1,300 patients with newly diagnosed wet AMD who had not previously been treated. Participants were randomly assigned to receive either faricimab on a personalized dosing schedule or aflibercept given every eight weeks. Both trials demonstrated that faricimab achieved vision outcomes that were noninferior to aflibercept, with patients gaining an average of approximately six letters on the visual acuity chart at one year. These findings established that the dual-pathway approach delivers comparable visual benefits to the existing standard of care.
One of the most clinically significant findings from the trials was that many patients treated with faricimab were able to extend their treatment intervals well beyond the standard monthly or bimonthly schedule used with earlier medications. By two years, the majority of faricimab-treated patients were being successfully maintained on treatment intervals of every three to four months. Patients in the faricimab group received a median of ten injections over two years, compared to fifteen injections for those on the fixed every-eight-week aflibercept schedule. For patients who require long-term treatment, this reduction in the number of annual injections represents a meaningful real-world benefit.
The two-year data from TENAYA and LUCERNE confirmed that the vision gains achieved during the first year were maintained through the second year of treatment. Improvements in retinal anatomy, including reduction in fluid and stabilization of retinal structure as measured by optical coherence tomography (a detailed imaging scan of the retina), were also sustained over time. The proportion of patients successfully treated at extended intervals continued to grow from year one to year two, suggesting that ongoing dual-pathway inhibition may support improved disease control over the long term. The safety profile at two years was comparable to aflibercept, with no new safety concerns identified.
What to Expect During Treatment
Faricimab is given as an injection directly into the eye by a retina specialist. Knowing what the treatment process involves can help patients feel more prepared and comfortable before their first appointment.
Treatment begins with a loading phase of four monthly injections. This initial phase establishes therapeutic levels of the medication inside the eye and brings the disease under early control. During this period, your retina specialist will monitor your response using optical coherence tomography imaging and visual acuity testing. After the loading phase, the specialist evaluates your disease activity and determines the appropriate interval for your ongoing treatment. Some patients may extend to every twelve or sixteen weeks, while others may need more frequent visits depending on how their retina responds. This personalized approach, sometimes called treat-and-extend, tailors your schedule to your individual needs.
Faricimab is administered as an intravitreal injection (an injection directly into the vitreous, the gel-filled interior of the eye) of 6 milligrams by a retina specialist in an office or clinic setting. Before the injection, numbing drops are applied and the eye surface is cleaned with antiseptic solution. The procedure itself takes only a few minutes, and most patients describe feeling brief pressure rather than significant pain. After the injection, your specialist may check your eye pressure and examine the retina before you leave. Mild, temporary effects such as floaters, slight redness, or minor irritation at the injection site are common and typically resolve within a day or two.
The side effects associated with faricimab are generally similar to those seen with other intravitreal injection treatments. Common, less serious effects include a small area of redness on the white of the eye (called a conjunctival hemorrhage), temporary increases in eye pressure, floaters, and mild eye discomfort. Less common but more serious risks include infection inside the eye (endophthalmitis), retinal detachment, tears in the retinal pigment epithelium (the supportive layer beneath the retina), and intraocular inflammation. The safety profile observed in the clinical trials was comparable to that of aflibercept.
Patients should contact their retina specialist promptly if they experience a sudden decrease in vision, worsening eye pain, significant new redness, or a sudden increase in flashes or floaters, as these symptoms may indicate a complication that requires urgent evaluation.
How Faricimab Compares to Other Treatments
Several effective medications are available for wet AMD, and choosing the right one involves weighing clinical evidence, individual disease characteristics, and practical considerations. Your retina specialist will help guide that decision based on your specific situation.
Ranibizumab (Lucentis) and aflibercept (Eylea) have long track records of effectiveness and are still widely used for wet AMD. Bevacizumab (Avastin) is another commonly used option that is administered off-label for this condition. High-dose aflibercept (Eylea HD) and faricimab represent newer additions that are designed with extended dosing intervals in mind. Each medication has its own clinical profile, mechanism of action, and dosing schedule. Your retina specialist will consider your disease features, any prior treatment history, and your personal circumstances when recommending the most appropriate option.
For many patients, the long-term demands of frequent injections, including travel, time away from daily activities, and the experience of the procedure itself, are among the most challenging aspects of managing wet AMD. Treatments that can maintain disease control with fewer annual visits offer a real quality-of-life benefit for patients and their families. The ability of faricimab to control disease at intervals of up to four months in many patients represents a potential advantage in reducing this treatment burden. It is important to understand, however, that not every patient will be able to extend to the longest intervals, and the schedule will always be adjusted based on how the retina is responding.
Frequently Asked Questions
Below are answers to questions our patients commonly ask about faricimab and how it fits into wet AMD care.
The key distinction is that faricimab targets two proteins, VEGF-A and Ang-2, while other currently approved wet AMD treatments target only the VEGF pathway. This additional mechanism addresses vascular instability and inflammation in a way that single-pathway medications do not. From a practical standpoint, the clinical trials showed that many patients on faricimab could maintain good disease control at intervals of up to four months, which is longer than the typical schedules for several other medications. It is worth noting that vision outcomes with faricimab were comparable to, rather than definitively better than, those achieved with aflibercept.
Switching from another treatment to faricimab is a clinical decision that depends on your current disease activity, how well your existing treatment is working, and your overall treatment goals. Some patients consider switching because their current medication is not adequately controlling fluid in the retina. Others may explore faricimab with the goal of extending the time between injections. Growing real-world evidence is helping retina specialists better understand outcomes for patients who switch. If you are considering a change, your specialist can review your imaging results and treatment history to determine whether faricimab is a reasonable next step.
It may, but this depends on how your retina responds to treatment. After the initial four-month loading phase, your retina specialist will assess whether your disease is stable enough to extend your dosing interval. In clinical trials, patients on faricimab received a median of roughly five injections per year after the loading phase, compared to approximately seven or eight per year for patients on a fixed bimonthly aflibercept schedule. Some patients successfully extend to every sixteen weeks, while others need more frequent treatment. Your schedule will always be individualized based on what the imaging shows at each visit, not set in advance.
Yes. Faricimab is FDA-approved for wet AMD, diabetic macular edema (swelling of the central retina caused by diabetes-related blood vessel damage), and retinal vein occlusion (a blockage in the veins that drain the retina). All three conditions involve abnormal vascular leakage and inflammation driven in part by the VEGF-A and Ang-2 pathways, which is why the dual-targeting mechanism of faricimab is relevant across these diagnoses. If you have been diagnosed with one of these conditions, ask your retina specialist whether faricimab may be appropriate for your care.
Most patients do well between injections, but it is important to stay alert to any changes in your vision. If you notice a sudden loss of vision, new or worsening distortion, a significant increase in floaters or flashes, or increasing pain and redness in the treated eye, contact your retina specialist right away rather than waiting for your next scheduled visit. These symptoms can occasionally signal a complication that needs prompt evaluation. Routine monitoring between visits, including the use of an Amsler grid at home to check for distortion, can also help you detect early changes.
Expert Wet AMD Care at Rhode Island Eye Institute
At Rhode Island Eye Institute, our fellowship-trained retina specialists, Gaurav Gupta, M.D. and Pranjal Thakuria, M.D., bring subspecialty expertise to every aspect of wet AMD care, from diagnosis through long-term management. We offer the full range of proven and emerging treatment options, including faricimab, so your care plan can be tailored to your specific needs and goals. If you have been diagnosed with wet AMD or have concerns about your vision, we welcome you to schedule a consultation with our retina team and experience the level of specialized care that has made us a trusted resource for patients throughout Rhode Island and beyond.